AZothBio utilizes an artificial intelligence-driven platform for the development of targeted drug delivery systems and the discovery of new drug candidates. This approach addresses the challenges of inefficient drug administration and the lengthy process of identifying effective therapeutic compounds.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug development faces challenges in efficiently delivering drugs to their intended targets and in rapidly identifying promising therapeutic compounds. Inefficient drug delivery limits drug efficacy and can cause systemic side effects, while lengthy drug discovery processes increase development costs and delay patient access to new treatments.
Solution
AZothBio leverages an artificial intelligence (AI)-driven platform to develop targeted drug delivery systems and discover novel drug candidates. Their AI platform analyzes vast datasets to optimize drug delivery, ensuring precise targeting and reduced off-target effects. The company's drug delivery platform focuses on creating nanoscale particles that can effectively transport nucleic acids into cells. AZothBio is also developing a pipeline of drug candidates, including AZB101, a selective TYK2-JH2 inhibitor for autoimmune diseases; AZB102, a selective TRKA inhibitor for NTRK fusion-positive tumors; and AZB301, a cell-penetrating peptide targeting the endoplasmic reticulum for tissue regeneration.
Target Audience
AZothBio's primary target audience includes pharmaceutical companies seeking innovative drug delivery technologies and novel drug candidates, as well as researchers and clinicians focused on autoimmune diseases, oncology, and regenerative medicine.
Features
- AI-driven platform for identifying and optimizing drug delivery systems
- Nanoparticle drug delivery technology for targeted nucleic acid delivery
- AZB101: TYK2-JH2 inhibitor targeting autoimmune diseases like psoriasis
- AZB102: TRKA inhibitor targeting NTRK fusion-positive solid tumors
- AZB301: Cell-penetrating peptide targeting the endoplasmic reticulum for tissue regeneration